Literature DB >> 2169213

[Comparison of the antithrombotic effects of heparin, enoxaparin and prostacycline in continuous hemofiltration].

D Journois1, D Safran, M H Castelain, D Chanu, C Drévillon, G Barrier.   

Abstract

Continuous anticoagulation is required during haemofiltration to prevent the deposition of fibrin and the formation of thrombus which would lead to early clotting of the haemofilter. This study aimed to compare the efficiencies of 3 different anticoagulation protocol: 150 IU.kg-1.day-1 heparin (group HEP), 1.2 mg.kg-1.day-1 enoxaparin (group ENX), and a combination of 0.8 mg.kg-1.day-1 enoxaparin with 5 ng.kg-1.min-1 prostaglandin I2 (group ENX and PGI2). A flat ANS69S (Hospal) haemofilter was used for continuous venovenous haemofiltration. Antithrombotic efficiency was assessed with a haemofilter permeability index (HPI) including the transmembraneous pressure gradient and the rate of production of ultrafiltrate. The time required for HPI to decrease to 1/3 of its initial value (HPI1/3) was used to compare the 3 protocols. Treatment tolerance was judged by monitoring the usual haemodynamic and haemostatic parameters. No adverse effects (bleeding, thrombosis, hypotension) were observed. HPI1/3 was 15.1 +/- 2.4 h, 18.3 +/- 3.1 h and 28.2 +/- 4.2 h in groups HEP, ENX and ENX and PGI2 respectively. High dose enoxaparin reached antithrombotic efficiency without increasing the risk of haemorrhage. The use of low doses of prostaglandin I2 greatly increased HPI1/3, without any deleterious haemodynamic effects. However, the high cost of prostaglandin I2 needs to be put in the balance with the increase in duration of haemofilter life. Therefore, further investigations are required to evaluate the possible synergy between heparin and prostaglandin I2, as well as the biological parameters which need to be monitored.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2169213     DOI: 10.1016/s0750-7658(05)80244-8

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  5 in total

Review 1.  Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?

Authors:  H M Oudemans-van Straaten; J P J Wester; A C J M de Pont; M R C Schetz
Journal:  Intensive Care Med       Date:  2006-02-02       Impact factor: 17.440

Review 2.  Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.

Authors:  S Noble; D H Peters; K L Goa
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

3.  Dual-lumen catheters for continuous venovenous hemofiltration: limits for blood delivery via femoral vein access and a potential alternative in an experimental setting in anesthetized pigs.

Authors:  Juliane K Unger; Klaus Pietzner; Roland C Francis; Juergen Birnbaum; Marc Michael Theisen; Arne-Joern Lemke; Stefan M Niehues
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

4.  Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.

Authors:  Anne-Cornélie J M de Pont; Jorrit-Jan H Hofstra; Derk R Pik; Joost C M Meijers; Marcus J Schultz
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

5.  Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.

Authors:  Yong Kyu Lee; Hae Won Lee; Kyu Hun Choi; Beom Seok Kim
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.